2021-2024: Active Acquirer Profiles in Women’s Health

We analyzed our annual Top 10 Deals blog series from 2021 - 2024 and identified the most active acquirer profiles in women’s health and sexual health.

Even in a tough IPO market, women’s health companies continue to exit with tremendous valuations. At Amboy Street, we started tracking these exits by kicking off our annual Top 10 Deals blog series in 2021. With our 2024 Top 10 Deals series now complete, we’re diving deeper—highlighting the most active acquirers shaping the future of women’s and sexual health.

Over the past four years, three key acquirer profiles have emerged:

Pharmaceutical / MedTech Giants:

Major players in Pharma and MedTech are actively acquiring in women’s health, expanding their portfolios through strategic deals. Companies like Hologic, Organon, Cooper Companies, and Boston Scientific are leading the charge.

See a list of transactions in this category from 2021-2024 below:

Private Equity Funds:

Private Equity funds are seeing the light and investing in this tremendous and underserved market. Reputable firms like Carlyle, KKR and L. Catterton are leading the way.

See a list of transactions in this category from 2021-2024 below:  

Consumer Packaged Goods (CPG) Conglomerates:

Global CPG giants like Reckitt, Kimberly-Clark, and Essity have long dominated the women’s and sexual health categories. With billions in annual revenue, these firms frequently acquire rather than build, expanding their market share through strategic purchases.

‍

See a list of transactions in this category from 2021-2024 below:

With increasing awareness, technological advancements, and growing consumer demand, we anticipate even more significant transactions in the years ahead. At Amboy Street, we remain committed to tracking and analyzing these deals, ensuring our community stays ahead of the latest trends shaping the future of women’s health.

Continue Reading

Top 10 Deals of 2026: ŌURA to Acquire Counsel Health for $625M

Every year, Amboy Street highlights the top 10 transactions in women’s health. The next deal in this year’s series is ŌURA’s agreement to acquire Counsel Health, an AI-native primary care company, for $625 million in cash.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Top 10 Deals of 2026: Sun Pharma to Acquire Organon for $11.75B

Every year, Amboy Street highlights the top 10 transactions in women’s health. This year’s series starts with one of the largest women’s health mergers in history.

Top 10 Deals of 2026: ŌURA to Acquire Counsel Health for $625M

Every year, Amboy Street highlights the top 10 transactions in women’s health. The next deal in this year’s series is ŌURA’s agreement to acquire Counsel Health, an AI-native primary care company, for $625 million in cash.

Top 10 Deals of 2026: Ferring to Acquire Gameto for up to $1.38B

Every year, Amboy Street highlights the top 10 transactions in women’s health. The splashy news of the week, and the next blog in our series, is Ferring Pharmaceuticals’ agreement to acquire Gameto, a cell-engineering company reimagining IVF, in a deal worth up to $1.38 billion.

Fast track our industry.
Get in touch today.